- +91 8471002000
- Messenger
Immunotherapy
Pembrolizumab
Pembrolizumab Injection
Injection
Brand name: Keytruda Manufacturer: Merck & Co., Inc.
Dosage of Pembrolizumab: 200mg via IV infusion, Q3W (every 3 weeks)
Pembrolizumab is authorized for treating various cancer forms, such as melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin's lymphoma, urothelial carcinoma, stomach cancer, esophageal cancer, and tumors exhibiting microsatellite instability or defective mismatch repair. This drug's purpose involves harnessing the immune system to boost the body's anti-tumor defenses.
Pembrolizumab represents a cutting-edge immunotherapy approach, aimed at harnessing a patient's immune system to identify and attack cancerous cells. Its mode of action involves obstructing the PD-1 protein utilized by cancer cells to elude immune responses. With this interference, pembrolizumab enables immune cells to detect and eliminate malignant cells. Demonstrating remarkable adaptability, this treatment has exhibited success across diverse cancer forms, signifying a transformative development in cancer therapy.
Resistance to pembrolizumab injection occurs when cancer cells adapt their molecular architecture to dodge immune checkpoint blockade, leading to hindered T-cell engagement, diminished display of tumor antigens, and amplified inhibitory components. This obstructs pembrolizumab's capacity to work effectively, lessening its potency against cancer.
Administering Pembrolizumab injection may lead to various side effects, including exhaustion, persistent cough, queasiness, and itchiness. In some cases, it may trigger intense outcomes, such as autoimmune assaults on normal organs, pulmonary irritation, hepatic difficulties, or critical infusion complications. Consistent supervision is crucial for early identification of these problems.
Pembrolizumab may be utilized in conjunction with several therapeutic agents, based on the particular cancer diagnosis. For example, non-squamous non-small cell lung cancer (NSCLC) treatment frequently involves the blend of pemetrexed, a platinum-based chemotherapy drug (either cisplatin or carboplatin), and pembrolizumab. Moreover, the FDA has sanctioned pembrolizumab's co-administration with axitinib to manage progressive renal cell carcinoma (RCC). It is crucial to seek a medical expert's guidance for tailored treatment choices.
Average price of Pembrolizumab Injection: ₹73,000 in India. The above price is specific for Dalhousie, Himachal Pradesh, India
WhatsApp us